Olanzapine: Safety Profile and Dosing Strategies

American Psychiatric Association . (1994). Diagnostic and statistical manual of mental disorders. (4th ed.). Washington, DC: Author.

Anonymous . (1980). Tardive dyskinesia scales in current use, in Fann, W. , Smith, R. C. , Davis, J. M. et al. (editors): Tardive dyskinesia research and treatment (pp. 243-267). Jamaica, NY: Spectrum Publications.

Barnes, T. R. , & Braude, W. M. (1985). Akathisia variants and tardive dyskinesia. Archives of General Psychiatry, 42, 874-878.

Beasley, C. M. , Sanger, T. , Satterlee, W. , Tollefson, G. , Tran, P. , Hamilton, S. , & The Olanzapine HGAP Study Group . (1996). Olanzapine versus placebo: Results of a double-blind, fixed dose olanzapine trial. Psychopharmacology, 124, 159-167.

Beasley, C. M. , Tollefson, G. , Tran, P. , Satterlee, W. , Sanger, T. , & Hamilton, S. (1996). Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 113-122.

Jeste, D. V. , & Wyatt, R. J. (1979). In search of treatment for tardive dyskinesia: Review of the literature. Schizophrenia Bulletin, 5, 253-293.

Kane, J. M. (1989). The current status of neuroleptic therapy. Journal of Clinical Psychiatry, 50, 322-328.

Keck, P. E. Jr. , & McElroy, S. L. (1996). Olanzapine: A novel antipsychotic medication. Todays Therapeutic Trends, 14, 3-75.

Ring, B. J. , Catlou, J. , Lindsay, T. J. , Gillespie, T. , Roskos, L. K. , Lerimele, B. D. , Swanson, S. P. , Hammon, M. A. , & Wrighton, S. A. (1996). Identification of the human cytochromes P-450 responsible for the in vitro formation of the antipsychotic olanzapine. Journal of Pharmacology and Experimental Therapeutics, 276, 658-666.

Simpson, G. M. , Amuso, D. , Blair, J. H. , & Farhas, T. (1964). Phenothiazine produced extrapyramidal disturbance. Archives General Psychiatry, 10, 127-136.

Tollefson, G. , Beasley, C. M. , Tran, P. , Dellva, M. A. , Krueger, J. , & Tamura, R. (1996, May/June). Olanzapine versus haloperdiol: Acute results of the multi-center international trial. New Clinical Drug Evaluation Unit Program abstract. Poster session presented at the New Clinical Drug Evaluation Unit Program, Boca Raton, FL.

Tran, P. V. , Beasley, C. M. , & Tollefson, G. D. (1995, December). Olanzapine. Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.

Tran, P. , Lu, Y. , Sanger, T. , Beasley, C. M. , & Tollefson, G. (1996, May/June). Olanzapine in the treatment of schizoaffective disorder. Poster session presented at the New Clinical Drug Evaluation Unit Program, Baca Raton, FL.

Van Putten, T. (1974). Why schizophrenic patients refuse their medication. Archives of General Psychiatry, 31, 67-72.

Zyprexa (olanzapine) Package Insert. (1996). Indianapolis, IN: Eli Lilly and Co.